Contribute Try STAT+ Today
Trending:
Coronavirus
First Opinion
Health
Pharmalot

STAT+ Latest

Columns: Adam’s TakePharmalot

Topics: BiotechPharmaPolicyHealth TechBusiness

Features: STAT+ Conversations CRISPR TrackrDrug Pricing Policy TrackerWebinars

Events: See upcoming events

Pharmalot

Pharmalittle: Pharma lobbies Congress on global tax proposal; the FDA doc at center of Aduhelm controversy

By Ed Silverman

Health Tech

STAT+ Conversations: A conversation on scrutiny facing Epic’s health care algorithms

By Megan Thielking

Painkillers
Pharmalot

Purdue says most creditors voted in favor of contentious bankruptcy plan

By Ed Silverman

Billy Dunn photo illustration
Biotech

How Biogen found a believer: At the FDA, a hard-nosed regulator was won over on controversial Alzheimer’s drug

By Nicholas Florko, Damian Garde, and Adam Feuerstein

Pharmalot

Pharmalittle: A race to develop Covid-19 pills is underway; Russian trolls target Pfizer vaccine

By Ed Silverman

Fecal Transplants FDA
Biotech

Microbiome therapy companies face the fallout of failed Seres trial

By Kate Sheridan

EPIC AI
A STAT Investigation

Epic’s AI algorithms, shielded from scrutiny by a corporate firewall, are delivering inaccurate information on seriously ill patients

By Casey Ross

Pharmalot Coming/Going STILL
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Biogen’s ‘symptom quiz’ for Aduhelm draws fire; most U.S. clinical trials flunk transparency rules

By Elizabeth Cooney

magnifying glass w/ reports
Pharmalot

Most clinical trials failed to meet U.S. transparency requirements for recently approved drugs

By Ed Silverman

Pharmalot

Pharmalittle: Biogen defends its controversial Alzheimer’s drug; critics pan Pfizer plan for Covid-19 shot production in Africa

By Ed Silverman

Seres Therapeutics
Biotech

Seres Therapeutics’ microbiome therapy for ulcerative colitis falls short in Phase 2 trial

By Kate Sheridan

Yellow pills
Health Tech

Happify to release prescription app to treat depression under loosened FDA rules

By Mario Aguilar

Pfizer Albert Bourla
Pharmalot

Pfizer looks to widen access to Covid-19 vaccine in Africa, but advocates say it doesn’t go far enough

By Ed Silverman

Pharmalot

Pharmalittle: Pfizer cuts deal for Covid-19 shot to be partially made in South Africa; wholesalers to pay $1.1b to NY to settle opioid suit

By Ed Silverman

therapy bot
Health Tech

Therapy chatbot startup Woebot raises $90 million

By Mario Aguilar

Paper cup pills nonadherent noncompliant
Pharmalot

FDA plans to study whether pharma reps at conference exhibit booths are telling the truth

By Ed Silverman

Road to Aduhelm illo
Biotech

Accelerated approval, the path used to greenlight Biogen Alzheimer’s drug, has a checkered track record, critics say

By Joanne Silberner

OPIOID photo ILLUSTRATION
Pharmalot

Three pharma wholesalers reach a $1.1 billion deal with New York over the opioid crisis

By Ed Silverman

Painkillers
Pharmalot

As a key hearing nears, Justice Department calls Purdue’s bankruptcy plan unconstitutional

By Ed Silverman

AWS
Health Tech

Amazon’s health cloud, Pichai on AI, and digital Alzheimer’s screens

By STAT staff

Pharma

STAT+ Conversations: the revitalization of the antibiotic drug pipeline

By Ed Silverman

Pharmalot

Pharmalittle: Wholesalers near deal over opioid litigation; pharma gives $67,400 to Peters for trying to torpedo drug pricing bill

By Ed Silverman

genetic sequencing/DNA
Biotech

Pacific Biosciences to buy smaller DNA sequencing firm for up to $800 million

By Matthew Herper

Tara Schwetz
Politics

San Francisco, Austin, or Raleigh? White House contemplates an out-of-D.C. address for new biomedical research agency

By Lev Facher

Scott Peters
Politics

Pharma CEOs, lobbyists showered Democrat with cash after his attempt to torpedo Pelosi’s drug pricing bill

By Rachel Cohrs

Patent folder
Pharmalot

Advocates urge Biden to name patent office director that could transform drug pricing

By Ed Silverman

money pile
Pharmalot

Dutch authorities fine drug maker $23 million for ‘excessive’ pricing of a rare disease drug

By Ed Silverman

Pharmalot

Pharmalittle: Pfizer seeks full FDA approval for its Covid-19 vaccine; CT attorney general calls some Sacklers ‘entitled thugs’

By Ed Silverman